ACER - The Buzz Show: Acer Therapeutics Inc. (NASDAQ: ACER) FDA Acceptance for ACER-001

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Acer Therapeutics Inc. and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001”

Acer Therapeutics Inc. (NASDAQ: ACER) climbed over 14% in premarket trading after the company and Relief Therapeutics announced FDA acceptance for the filing of a new drug application for ACER-001.

The FDA has accepted for filing the New Drug Application for ACER-001, to be used in the treatment of patients with Urea Cycle Disorders and has assigned a Prescription Drug User Fee Act target action date of June 5th, 2022 multidrug-resistant microorganisms, or MDROs.

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

For more information, please visit: Acer Therapeutics Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Acer Therapeutics Inc. (NASDAQ: ACER) FDA Acceptance for ACER-001 first appeared on Financial Buzz .

For further details see: